| Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo … R Landewé, J Braun, A Deodhar, M Dougados, WP Maksymowych, ... Annals of the rheumatic diseases, annrheumdis-2013-204231, 2013 | 553 | 2013 |
| Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study W Oertel, C Trenkwalder, H Beneš, L Ferini-Strambi, B Högl, W Poewe, ... The Lancet Neurology 10 (8), 710-720, 2011 | 154 | 2011 |
| Rotigotine improves restless legs syndrome: A 6‐month randomized, double‐blind, placebo‐controlled trial in the United States WA Hening, RP Allen, WG Ondo, AS Walters, JW Winkelman, P Becker, ... Movement disorders 25 (11), 1675-1683, 2010 | 122 | 2010 |
| Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study WH Oertel, H Beneš, D Garcia-Borreguero, B Högl, W Poewe, ... Sleep medicine 11 (9), 848-856, 2010 | 106 | 2010 |
| Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: Results from a single-blind randomized phase IV trial AJ Kivitz, J Schechtman, M Texter, A Fichtner, M de Longueville, ... The Journal of rheumatology 41 (4), 648-657, 2014 | 83 | 2014 |
| Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease N Giladi, A Fichtner, W Poewe, B Boroojerdi Journal of neural transmission 117 (12), 1395-1399, 2010 | 52 | 2010 |
| Augmentation in the treatment of restless legs syndrome with transdermal rotigotine H Beneš, D García-Borreguero, L Ferini-Strambi, E Schollmayer, ... Sleep medicine 13 (6), 589-597, 2012 | 51 | 2012 |
| Pharmacokinetics of Lacosamide and Omeprazole Coadministration in Healthy Volunteers: Results from a Phase I, Randomized, Crossover Trial W Cawello, C Mueller-Voessing, A Fichtner Clinical drug investigation 34 (5), 317-325, 2014 | 30 | 2014 |
| Effect of certolizumab pegol on signs and symptoms of ankylosing spondyltitis and non-radiographic axial spondyloarthritis: 24 week results of a double blind randomized placebo … R Landewe, M Rudwaleit, D van der Heijde, M Dougados, ... ARTHRITIS AND RHEUMATISM 64 (10), S336-S337, 2012 | 22 | 2012 |
| Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the RAPID 2 study J Smolen, R Van Vollenhoven, A Kavanaugh, A Fichtner, V Strand, ... JOURNAL OF RHEUMATOLOGY 38 (6), 1152-1152, 2011 | 14 | 2011 |
| Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1-3 mg/24 h for up to 5 years E Dohin, B Högl, L Ferini-Strambi, E Schollmayer, A Fichtner, L Bauer, ... Expert opinion on pharmacotherapy 14 (1), 15-25, 2013 | 12 | 2013 |
| Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine W Cawello, A Fichtner, H Boekens, M Braun European journal of drug metabolism and pharmacokinetics 39 (3), 155-163, 2014 | 11 | 2014 |
| Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 12 Week Magnetic Resonance Imaging results of a Phase 3 … D van der Heijde, WP Maksymowych, R Landewe, C Stach, B Hoepken, ... ARTHRITIS AND RHEUMATISM 64 (10), S730-S730, 2012 | 8 | 2012 |
| Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12-week magnetic resonance imaging results of RAPID-axSpA … D Van der Heijde, WP Maksymowych, R Landewé, C Stach, B Hoepken, ... ANNALS OF THE RHEUMATIC DISEASES 72, 515-516, 2013 | 7 | 2013 |
| Stability of rotigotine plasma levels during long-term transdermal application for patients with idiopathic restless legs syndrome J Whitesides, W Cawello, M Braun, A Fichtner, W Oertel MOVEMENT DISORDERS 26, S365-S365, 2011 | 3 | 2011 |
| Long-Term Safety and Efficacy of Rotigotine in Patients with Idiopathic RLS: 5-Year Results from a Prospective Multinational Open-Label FollowUp Study B Hogl, C Trenkwalder, D Garcia-Borreguero, R Kohnen, W Poewe, ... Neurology 74 (9), A106-A106, 2010 | 3 | 2010 |
| Long-term treatment with transdermal rotigotine in patients with idiopathic restless legs syndrome (RLS): results from a 12-month open-label extension trial RP Allen, J Winkelman, W Ondo, A Fichtner, E Schollmayer Sleep 33, A251-A251, 2010 | 3 | 2010 |
| Effect of certolizumab pegol on signs and symptoms of axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24-week results of … R Landewé, M Rudwaleit, D van der Heijde, M Dougados, ... ANNALS OF THE RHEUMATIC DISEASES 72, 86-87, 2013 | 2 | 2013 |
| Assessment of immune responses to pneumococcal and influenza vaccines in patients with rheumatoid arthritis receiving certolizumab pegol A Kivitz, J Schechtman, M Texter, A Fichtner, E Chartash Arthritis and Rheumatism 63 (10), S488-S488, 2011 | 2 | 2011 |
| Augmentation of Restless Legs Syndrome (RLS) under Rotigotine: Results from a 5-Year Prospective, Multinational, Open-Label Study D Garcia-Borreguero, H Benes, L Ferini-Strambi, B Hoegl, W Oertel, ... NEUROLOGY 76 (9), A370-A370, 2011 | 2 | 2011 |
